The most promising targets for a cancer vaccine might not be hiding in the usual places. For decades, immunotherapy research has focused on a limited set of genetic instructions, hunting for tumor-specific antigens in the well-mapped regions of the genome. A Montreal-based startup, Epitopea, is betting that the real treasure lies in the so-called junk.
Founded in 2021 as an academic spinout, the company is developing RNA-based immunotherapies that target antigens encoded by overlooked, non-canonical genomic sequences, which it calls Cryptigens. The core idea is both elegant and ambitious: if these antigens are truly unique to cancer cells and shared across many patients, they could form the basis for an effective, off-the-shelf vaccine. It’s a bet that has attracted over $45 million in funding and, more critically, regulatory approval to begin its first clinical trial in advanced ovarian cancer [Epitopea, retrieved 2026].
A Platform Built on 'Cryptigens'
Epitopea’s proprietary CryptoMap platform is the engine of this search. It combines spatial immunopeptidomics, genomics, and bioinformatics to scan non-canonical genomic regions,areas often dismissed as genetic noise,for peptides presented by cancer cells but absent from healthy tissue [CQDM, retrieved 2026]. The goal is to build a library of these shared tumor-specific antigens, moving away from the highly individualized neoantigen approaches that dominate much of the personalized cancer vaccine field.
“The platform searches non-canonical genomic regions for tumour-specific antigens and uses them as targets for cancer immunotherapies,” the company stated in a 2022 profile [BioWorld, May 2022]. By focusing on antigens that are broadly expressed across a cancer type, Epitopea aims to create accessible, off-the-shelf treatments, a proposition with potentially simpler manufacturing and distribution than bespoke therapies [Epitopea, February 2025].
From Academic Insight to Clinical Acceleration
The science originates from the labs of academic co-founders Claude Perreault and Pierre Thibault at the University of Montreal’s Institute for Research in Immunology and Cancer (IRIC) [BioWorld, May 2022]. The company’s leadership has since evolved to include seasoned commercial operators. In July 2024, Alan C. Rigby, described by the company as an experienced oncology-focused biotech entrepreneur, succeeded Jon Moore as CEO. Moore, an operating partner at founding investor Advent Life Sciences, transitioned to the role of Chief Scientific Officer [Epitopea, July 2024].
The appointment of Klaus Edvardsen as Chief Medical Officer in early 2025 further signaled a push toward clinical development. Edvardsen brings a track record of leading oncology drug development from concept to regulatory approval [Epitopea, February 2025]. This experienced team has guided the company through two significant funding rounds.
| Date | Round | Amount (USD) | Lead Investor(s) |
|---|---|---|---|
| April 2022 | Seed | $14 million | Advent Life Sciences [PR Newswire, April 2022] |
| October 2024 | Pre-Series A | $31 million | Investissement Québec [BetaKit, October 2024] |
The $31 million pre-Series A round, which included new investors adMare BioInnovations and Jonathan Milner alongside existing backers, is explicitly fueling the company’s clinical ambitions [BetaKit, October 2024].
The First Clinical Milestone
That capital is now at work. Epitopea’s lead candidate, CryptiVax-1001, is an off-the-shelf mRNA therapeutic vaccine [Drug Discovery World, retrieved 2026]. In 2025, the company received approval for its OVACT Clinical Trial Application, clearing the path for a Phase 1/1b study. The trial is designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 in patients with HRP+/BRCA-wildtype high-grade serous ovarian cancer [The Canadian Press News, retrieved 2026].
This is the critical first test of Epitopea’s core hypothesis in humans. Success in this trial would not only validate the Cryptigen approach but also position the company in a space with significant unmet need. Ovarian cancer, particularly in its advanced stages, remains a devastating disease with limited durable treatment options.
The Risks in the Bet
The promise is substantial, but the path is lined with the inherent risks of novel biologic drug development. The company’s entire thesis rests on a few pivotal, yet unproven, assumptions. A cautious look reveals three primary challenges.
- Antigen Validation. The fundamental science,that Cryptigens are truly tumor-specific, immunogenic, and shared across a meaningful patient population,must be confirmed in the clinic. Early preclinical data is promising, but human immune systems are complex and unpredictable.
- Clinical Efficacy. Demonstrating safety and an immune response in Phase 1 is one hurdle. Proving that this immune response translates into a meaningful clinical benefit, such as prolonged survival or disease control, is the far greater challenge that lies ahead in later-stage trials.
- Competitive Landscape. While no direct competitors are named in public sources, Epitopea is not operating in a vacuum. The field of cancer vaccines, both personalized and off-the-shelf, is crowded and advancing rapidly. Large pharmaceutical companies and well-funded biotechs are pursuing similar goals with different technological angles.
Epitopea’s answer to these risks is its platform depth and strategic focus. The company is not betting on a single antigen but on a discovery engine designed to populate a pipeline. The choice of ovarian cancer as a first indication is strategic, targeting a clear need where new modalities are urgently sought.
What Standard Care Looks Like Today
For patients with advanced high-grade serous ovarian cancer, the current standard of care often involves a combination of aggressive surgery and platinum-based chemotherapy. While effective initially, many patients experience relapse. Subsequent lines of treatment can include PARP inhibitors (for those with specific genetic mutations), anti-angiogenic drugs, or further chemotherapy, but options become increasingly limited and less effective over time [Clinical Practice Guidelines]. The prognosis remains poor, underscoring the acute need for novel therapeutic approaches like immunotherapy that could offer a more durable response.
The next twelve months for Epitopea will be defined by the clinic. Patient enrollment and initial data readouts from the OVACT trial will provide the first real-world evidence of whether mining the genome’s overlooked regions can yield a new class of cancer therapy. Positive early signals would likely trigger a Series A round to expand into additional cancer indications, such as lung cancer, which the company has also cited as a target [Clémence Tremblay LinkedIn, retrieved 2026]. For now, the bet is clear: the key to a better cancer vaccine was hidden in plain sight, written in the genome’s forgotten code.
Sources
- [Epitopea, retrieved 2026] Home - Epitopea | https://www.epitopea.com/
- [BioWorld, May 2022] Epitopea Featured in BioWorld | https://www.epitopea.com/epitopea-featured-in-bioworld/
- [PR Newswire, April 2022] Epitopea Announces $14 Million Financing | https://www.prnewswire.co.uk/news-releases/epitopea-announces-14-million-financing-to-advance-cancer-immunotherapeutics-890240223.html
- [Epitopea, July 2024] Leadership Transition Announcement | https://www.epitopea.com/epitopea-announces-leadership-transition-and-new-appointments/
- [BetaKit, October 2024] Epitopea raises $43 million CAD | https://betakit.com/epitopea-raises-43-million-cad-for-rna-based-cancer-immunotherapies/
- [Epitopea, February 2025] Chief Medical Officer Appointment | https://www.epitopea.com/epitopea-announces-approval-of-ovact-clinical-trial-application-for-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer/
- [CQDM, retrieved 2026] Platform Development Announcement | https://www.epitopea.com/cqdm-epitopea-fund-development-cryptomap-enabling-development-of-rna-based-immunotherapies/
- [Drug Discovery World, retrieved 2026] CryptiVax-1001 profile | https://www.drugdiscoveryworld.com/
- [The Canadian Press News, retrieved 2026] OVACT Trial Design | https://www.thecanadianpressnews.ca/
- [Clémence Tremblay LinkedIn, retrieved 2026] Professional profile | https://www.linkedin.com/in/cl%C3%A9mence-tremblay-2b521115a/?_l=en